Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience-Reference-Cited by-同舟云学术

Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience

Published:2022-08-05 Issue:9 Volume:18 Page:879-888
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Dos Santos Jéssica Barreto Ribeiro¹^ORCID,Gomes Rosângela Maria²^ORCID,da Silva Michael Ruberson Ribeiro¹^ORCID

Affiliation:

1. Department of Pharmacy and Nutrition, Health Economics and Technology Assessment Group; Center for Exact, Natural and Health Sciences, Federal University of Espírito Santo, Alegre, Brazil

2. Department of Management and Incorporation of Technologies and Innovation in Health; Secretariat of Science, Technology and Strategic Inputs; Ministry of Health of Brazil, Brazil

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2022.2106972

Reference47 articles.

1. Generalized Myasthenia Gravis

2. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology

3. De Haard J, Dreier T, Ulrichts P, et al. Use of FcRn antagonists for treatment of generalized myasthenia gravis. World Intellectual Property Organization patent WO 2019/110823 A1. 2019 June. Available in: https://patents.google.com/patent/WO2019110823A1/en.

4. The Incidence of Myasthenia Gravis: A Systematic Literature Review

5. The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control;Biomedicines;2024-05-30

2. Efgartigimod as a novel FcRn inhibitor for autoimmune disease;Neurological Sciences;2024-04-22

3. An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin;Journal of Clinical Investigation;2024-02-15

4. Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future;CNS Drugs;2024-01

5. Serum Pentaxin 3 (PTX3) Promotes NLRP3 Inflammasome and Pyroptosis in Patients with Up-Regulated Myasthenia Gravis;Frontiers in Bioscience-Landmark;2023-11-28